ACRV (STOCKS)
Acrivon Therapeutics, Inc. Common Stock
$1.600000
+0.040000 (+2.56%)
Prev close: $1.560000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Peter Blume-Jensen
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $62.65M
- Employees
- 78
- P/E (TTM)
- -0.77
- P/B (TTM)
- 0.44
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
4
Strong Buy
9
Buy
2
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$-0.52 | $-0.48 | -0.0444 | -9.34% |
|
Sep 2025 (Q3)
|
$-0.47 | $-0.60 | +0.1318 | +21.90% |
|
Jun 2025 (Q2)
|
$-0.55 | $-0.60 | +0.0480 | +8.03% |
|
Mar 2025 (Q1)
|
$-0.51 | $-0.66 | +0.1451 | +22.15% |
Financial Statements
| Revenues | $0.00 |
| Nonoperating Income/Loss | $6.21M |
| Operating Expenses | $84.11M |
| Research and Development | $59.99M |
| Other Operating Expenses | $24.12M |
| Operating Income/Loss | -$84.11M |
| Income/Loss From Continuing Operations After Tax | -$77.83M |
| Income/Loss From Continuing Operations Before Tax | -$77.83M |
| Income Tax Expense/Benefit | $0.00 |
| Net Income/Loss | -$77.91M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$77.91M |
| Net Income/Loss Available To Common Stockholders, Basic | -$77.91M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$2.02 |
| Diluted Earnings Per Share | -$2.02 |
| Basic Average Shares | 38,509,281 |
| Diluted Average Shares | 38,509,281 |
| Assets | $129.72M |
| Current Assets | $120.45M |
| Noncurrent Assets | $9.27M |
| Fixed Assets | $4.89M |
| Other Non-current Assets | $4.38M |
| Liabilities | $17.20M |
| Current Liabilities | $15.66M |
| Accounts Payable | $2.28M |
| Other Current Liabilities | $13.39M |
| Noncurrent Liabilities | $1.54M |
| Equity | $112.52M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $112.52M |
| Liabilities And Equity | $129.72M |
| Net Cash Flow From Operating Activities | -$63.67M |
| Net Cash Flow From Operating Activities, Continuing | -$63.67M |
| Net Cash Flow From Investing Activities | $66.10M |
| Net Cash Flow From Investing Activities, Continuing | $66.10M |
| Net Cash Flow From Financing Activities | -$749.00K |
| Net Cash Flow From Financing Activities, Continuing | -$749.00K |
| Net Cash Flow | $1.69M |
| Net Cash Flow, Continuing | $1.69M |
| Comprehensive Income/Loss | -$78.24M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$78.24M |
| Other Comprehensive Income/Loss | -$336.00K |